AR056369A1 - Compuestos derivados de quinazolina y composicion farmaceutica - Google Patents
Compuestos derivados de quinazolina y composicion farmaceuticaInfo
- Publication number
- AR056369A1 AR056369A1 ARP060102205A ARP060102205A AR056369A1 AR 056369 A1 AR056369 A1 AR 056369A1 AR P060102205 A ARP060102205 A AR P060102205A AR P060102205 A ARP060102205 A AR P060102205A AR 056369 A1 AR056369 A1 AR 056369A1
- Authority
- AR
- Argentina
- Prior art keywords
- quinazoline
- pharmaceutical composition
- compounds derived
- formula
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de formula (1) util en el tratamiento de enfermedades, en particular enfermedades proliferativas como por ejemplo cáncer y para utilizar en la preparacion de medicamentos para su uso en el tratamiento de enfermedades proliferativas; procesos para la preparacion de dichos compuestos, así como composiciones farmacéuticas que los contienen como ingrediente activo. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1), o una sal o prodroga del mismo, donde R1 es hidrogeno o metilo y X es un enlace u oxígeno.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0510963A GB0510963D0 (en) | 2005-05-28 | 2005-05-28 | Chemical compounds |
| GB0600743A GB0600743D0 (en) | 2006-01-14 | 2006-01-14 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056369A1 true AR056369A1 (es) | 2007-10-10 |
Family
ID=36753382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102205A AR056369A1 (es) | 2005-05-28 | 2006-05-26 | Compuestos derivados de quinazolina y composicion farmaceutica |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080194556A1 (es) |
| EP (1) | EP1888572A1 (es) |
| JP (1) | JP2008542345A (es) |
| AR (1) | AR056369A1 (es) |
| TW (1) | TW200716618A (es) |
| UY (1) | UY29561A1 (es) |
| WO (1) | WO2006129064A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA04006260A (es) * | 2001-12-24 | 2005-03-31 | Astrazeneca Ab | Derivados de quinazolina sustituidos como inhibidores de cinasas aurora. |
| GB0601215D0 (en) * | 2006-01-21 | 2006-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2010068951A1 (en) * | 2008-12-12 | 2010-06-17 | Fox Chase Cancer Center | Combination therapy based on src and aurora kinase inhibition for the treatment of cancer |
| ES2541054T3 (es) * | 2010-10-20 | 2015-07-15 | Université De Bordeaux | Firmas del resultado clínico en tumores estromales gastrointestinales y método de tratamiento de tumores estromales gastrointestinales |
| JP5965499B2 (ja) | 2012-12-25 | 2016-08-03 | 日本曹達株式会社 | ハロゲン化アニリンおよびその製造方法 |
| JP6527513B2 (ja) | 2013-11-20 | 2019-06-05 | シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｔａｍファミリーキナーゼ阻害剤としてのキナゾリン誘導体 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0409427A (pt) * | 2003-04-16 | 2006-04-18 | Astrazeneca Ab | composto, uso do mesmo, composição farmacêutica, método de tratamento de um humano sofrendo de uma doença hiperproliferativa, e, processo para a preparação de um composto ou de um sal, éster ou pró-droga farmaceuticamente aceitáveis do mesmo |
-
2006
- 2006-05-24 EP EP06727154A patent/EP1888572A1/en not_active Withdrawn
- 2006-05-24 JP JP2008514177A patent/JP2008542345A/ja active Pending
- 2006-05-24 US US11/914,474 patent/US20080194556A1/en not_active Abandoned
- 2006-05-24 WO PCT/GB2006/001911 patent/WO2006129064A1/en not_active Ceased
- 2006-05-25 UY UY29561A patent/UY29561A1/es not_active Application Discontinuation
- 2006-05-26 TW TW095118869A patent/TW200716618A/zh unknown
- 2006-05-26 AR ARP060102205A patent/AR056369A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1888572A1 (en) | 2008-02-20 |
| UY29561A1 (es) | 2006-12-29 |
| TW200716618A (en) | 2007-05-01 |
| US20080194556A1 (en) | 2008-08-14 |
| JP2008542345A (ja) | 2008-11-27 |
| WO2006129064A1 (en) | 2006-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| AR056369A1 (es) | Compuestos derivados de quinazolina y composicion farmaceutica | |
| AR068369A1 (es) | Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina" | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| CR11482A (es) | Derivados de 1,2,3-triazol para uso como inhibidores de estearoil-coenzima a desaturasa | |
| UY30759A1 (es) | Compuestos quimicos | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| ATE473975T1 (de) | Chemische verbindungen | |
| ATE398613T1 (de) | Chemische verbindungen | |
| PA8591701A1 (es) | Derivados de pirrolopirimidina | |
| CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| UY30051A1 (es) | Derivados de pirimidina para el tratamiento del crecimiento celular anormal | |
| EA201001196A1 (ru) | Соединения 4-пиридинона и их применение для лечения рака | |
| UY28271A1 (es) | Compuestos químicos | |
| MX2009013501A (es) | Compuestos piperidinicos y sus usos. | |
| ECSP099382A (es) | Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
| ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
| UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| UY28366A1 (es) | Compuestos químicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |